Bachem Holding AG
SIX:BANB

Watchlist Manager
Bachem Holding AG Logo
Bachem Holding AG
SIX:BANB
Watchlist
Price: 67.5 CHF -3.3% Market Closed
Market Cap: 5.1B CHF
Have any thoughts about
Bachem Holding AG?
Write Note

Bachem Holding AG
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bachem Holding AG
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Bachem Holding AG
SIX:BANB
Income from Continuing Operations
CHf113.6m
CAGR 3-Years
5%
CAGR 5-Years
18%
CAGR 10-Years
16%
Siegfried Holding AG
SIX:SFZN
Income from Continuing Operations
CHf128.8m
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Income from Continuing Operations
CHf574m
CAGR 3-Years
4%
CAGR 5-Years
-2%
CAGR 10-Years
12%
Tecan Group AG
SIX:TECN
Income from Continuing Operations
CHf101.3m
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Income from Continuing Operations
-€51.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Income from Continuing Operations
CHf27.9m
CAGR 3-Years
34%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Bachem Holding AG
Glance View

Market Cap
5.1B CHF
Industry
Life Sciences Tools & Services

Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

BANB Intrinsic Value
90.95 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Bachem Holding AG's Income from Continuing Operations?
Income from Continuing Operations
113.6m CHF

Based on the financial report for Jun 30, 2024, Bachem Holding AG's Income from Continuing Operations amounts to 113.6m CHF.

What is Bachem Holding AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
16%

Over the last year, the Income from Continuing Operations growth was 15%. The average annual Income from Continuing Operations growth rates for Bachem Holding AG have been 5% over the past three years , 18% over the past five years , and 16% over the past ten years .

Back to Top